Stockscreener 앱 받기
18.19
1.52%
-0.28
시간 외 거래:
18.11
-0.08
-0.44%
전일 마감가:
$18.47
열려 있는:
$18.5
하루 거래량:
653.59K
Relative Volume:
0.61
시가총액:
$1.34B
수익:
-
순이익/손실:
$-230.32M
주가수익비율:
-5.159
EPS:
-3.5259
순현금흐름:
$-196.04M
1주 성능:
+3.65%
1개월 성능:
+5.63%
6개월 성능:
+43.57%
1년 성능:
-52.77%
1일 변동 폭
$18.00
$18.75
1주일 범위
$15.76
$18.75
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.19 | 1.36B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 업그레이드 | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? - simplywall.st
MLTX stock soars overnight after FDA backs skin drug filing — analyst sees over 300% upside on 'best-in-class' label - MSN
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors? - Kavout
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
MoonLake (MLTX) shares gain after positive FDA meeting on sonelokimab filing - MSN
MoonLake clears a key regulatory hurdle, and shares rocket - MSN
MLTX Technical Analysis | Trend, Signals & Chart Patterns | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive FDA Pre BLA Outcome For Sonelokimab - simplywall.st
FDA aligns with MoonLake on lead drug submission plans, stock soars - MSN
Cormorant Asset Management and Bihua Chen report 6.25% stake in MoonLake (MLTX) - Stock Titan
(MLTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
Insider Sell Alert: Matthias Bodenstedt Sells Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
MoonLake Immunotherapeutics (MLTX) CFO logs pre-planned sale of 13,653 shares - Stock Titan
Equities Analysts Set Expectations for MLTX Q1 Earnings - MarketBeat
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $45 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA Pathway - Yahoo Finance
Needham raises Moonlake stock price target to $30 on BLA filing plans - Investing.com
Needham raises Moonlake stock price target to $30 on BLA filing plans By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained - TipRanks
Update: MoonLake Immunotherapeutics Q1 Net Loss Widens - Moomoo
MoonLake Gains FDA Clearance for Sonelokimab Hidradenitis Suppurativa Label - The Clinical Trial Vanguard
MoonLake price target raised to $45 from $40 at H.C. Wainwright - TipRanks
Down-But-Not-Out Biotech Rockets On A Key FDA Decision - Investor's Business Daily
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $70 - 富途牛牛
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
H.C. Wainwright raises Moonlake stock price target on FDA progress - Investing.com UK
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars - Benzinga
MoonLake Immunotherapeutics Announces Positive FDA Pre-BLA Meeting and Reports Q1 2026 Financial Results - Minichart
H.C. Wainwright raises Moonlake stock price target on FDA progress By Investing.com - Investing.com Australia
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):